Detalhe da pesquisa
1.
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Lancet
; 397(10287): 1809-1818, 2021 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33964223
2.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32702298
3.
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Lancet Infect Dis
; 24(5): 465-475, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38342107
4.
Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies.
PLoS One
; 18(5): e0286117, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37220123
5.
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-É£ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
J Immunol Methods
; 523: 113584, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37918618
6.
Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium.
Front Immunol
; 13: 982887, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36341380
7.
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Front Immunol
; 13: 984642, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36159843
8.
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Lancet Microbe
; 3(9): e663-e671, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35907430
9.
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Front Immunol
; 13: 795463, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35197971
10.
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Lancet Infect Dis
; 22(12): 1728-1736, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36087586
11.
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.
Vaccines (Basel)
; 9(3)2021 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33809415
12.
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS).
Vaccines (Basel)
; 9(8)2021 Aug 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34451976
13.
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Nat Commun
; 12(1): 4636, 2021 07 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34330906
14.
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
PLoS One
; 16(9): e0256980, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34495988
15.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(2): 279-288, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33335322
16.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33335323
17.
Factors influencing the re-emergence of plague in Madagascar.
Emerg Top Life Sci
; 4(4): 411-421, 2020 12 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33258957
18.
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Lancet Infect Dis
; 20(7): 816-826, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32325038
19.
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line.
Vaccines (Basel)
; 7(1)2019 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-30909516
20.
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine.
Vaccines (Basel)
; 7(2)2019 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31096710